65 results about "Kidney Failures" patented technology

The invention relates to a weight loss intervention method and device for chronic renal failure and obesity patients based on an individualized prescription. The method comprises the following steps: constructing a multi-modal dynamic time sequence feature vector of a patient; identifying and quantifying potential causal effects of different weight loss intervention measures on physiological outcomes of renal functions, electrolyte balance, anemia states, bone mineral metabolism and weight indexes of the CKD patient according to a dual robust estimator; dynamically constructing a weight loss intervention measure causal model according to the potential causal effect of the physiological outcome of each patient and the physiological and pathological background; and inputting the multi-modal dynamic time sequence feature vector of the patient into a weight loss intervention measure causal model, and generating a daily diet scheme, an exercise scheme and corresponding high-confidence risk early warning and causal explanation of the patient. The method overcomes the limitation that the traditional method only pays attention to correlation and cannot clearly determine the intervention effect, ensures that the causal atlas and the intervention scheme are optimized according to the real-time change state of the patient, and realizes a real dynamic prescription.

The utility model provides a bioreactor device for replacing the function of a renal tubule, the bioreactor device is placed in a cell culture incubator, the bioreactor device comprises a fixed frame and a chip, the chip is arranged on the fixed frame, and a vein-imitated renal tubule structure is formed in the chip; openings in the two ends of the flow channel are respectively a liquid inlet and a liquid outlet; the inner diameter of the main flow channel is larger than that of the micro flow channel; wherein the inner diameter of the main flow channel and the inner diameter of the micro flow channel of the chip are both within the pipe diameter range of the physiological renal tubule; a human renal tubular epithelial cell suspension enters the vein-imitating flow channel from the liquid inlet and is attached to the inner wall of the vein-imitating flow channel. Therefore, the structure of the renal tubule is reflected in a more bionic and more reasonable manner, the physiological environment of the renal tubule can be simulated more accurately, a new design thought and method are provided for a renal tubule bioreactor device in a bioartificial kidney, the difficulty in the field of kidney replacement therapy is expected to be solved, and the life quality of patients with end-stage renal failure due to nephropathy is improved.

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

The application discloses a Bifidobacterium longum subsp.longum strain for relieving pathological characteristics of mice with chronic kidney disease induced by adenine, and belongs to the technical fields of microorganisms and medicines.The application provides a biomarker combination related to end-stage renal disease of peritoneal dialysis, wherein the corresponding species abundance in the biomarker combination presents significant difference in matched healthy control population and peritoneal dialysis population, can effectively distinguish the end-stage renal disease population of peritoneal dialysis and the healthy population, and has high sensitivity and specificity.The application also provides a Bifidobacterium longum subsp.longum strain CCFM1375 capable of delaying the progression of renal failure, which can be used for preparing products for improving chronic kidney disease.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The application discloses a hemodialysis sufficiency evaluation method based on sodium balance, and relates to the technical field of hemodialysis, and the method comprises the following steps: obtaining the body weight, dry body weight and serum sodium concentration of a patient before dialysis; calculating a target sodium removal amount Na_target=DeltaW* [Na]s / 0.93, and establishing a quantitative equivalent relationship between the body weight increase and sodium accumulation; obtaining or calculating an actual sodium removal amount (including two ways of convection and diffusion); calculating a sodium removal ratio R_Na=Na_actual / Na_target; and evaluating the dialysis sufficiency according to the R_Na. The application firstly changes the dialysis sufficiency evaluation from 'urea removal' to'sodium and water removal', and directly aims at the main pathological burden of kidney failure patients, i.e. sodium and water retention. The sodium removal ratio R_Na is more directly related to the volume state and cardiovascular prognosis of the patient than the traditional Kt / V index. The method only needs the body weight and serum sodium before and after dialysis to be calculated, and can be integrated into the existing dialysis information system.

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

A medical device system includes renal failure therapy machines each including a memory. The renal failure therapy machines are communicatively coupled such that the memories collectively form a distributed database. The system also includes a logic implementer associated with each renal failure therapy machine. Each logic implementer is programmed to automatically access the distributed database, so that each renal failure therapy machine periodically delivers prescription input parameters and / or treatment output data to at least one of the other renal failure therapy machines, and retrieves prescription input parameters and / or treatment output data from at least one of the other renal failure therapy machines. One of the renal failure therapy machines is configured to create at least one treatment record trend from the treatment output data and to share the at least one treatment record trend with other renal failure therapy machines through the distributed database.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using as says that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

An extracorporeal and drug delivery system includes (i) a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including (a) an effluent pump for pumping effluent from the blood filter at an effluent flowrate, and at least one of (b) a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flowrate, (c) a predilution pump for pumping replacement fluid into the arterial line at a predilution flowrate, or (d) a postdilution pump for pumping replacement fluid into the venous line at a postdilution flowrate; (ii) an infusion pump operable to deliver an intravenous (“IV”) drug to the patient at an IV drug flowrate; and (iii) a coordinating logic implementor configured to adjust the IV drug flowrate based on an amount of the IV drug removed via the effluent flowrate.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube, and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the local disinfection.

The invention provides a peritoneal dialysis device for renal failure, and belongs to the technical field of peritoneal dialysis. Comprising a positioning disc, an in-vivo dialysis tube, an in-vitro dialysis tube and a buffering assembly, the in-vivo dialysis tube and the in-vitro dialysis tube are installed on the positioning disc, the buffering assembly is used for buffering traction force on the in-vitro dialysis tube, the buffering assembly is further used for supporting and positioning the in-vivo dialysis tube, and the buffering assembly is connected with the positioning disc and a positioning plate. By arranging the buffer assembly, the in-vivo dialysis tube can be plastically fixed, the phenomenon that the in-vivo dialysis tube deviates and floats upwards after being used in the body of a patient for a long time is prevented, the difficulty of peritoneal dialysis operation of the patient is reduced, redundant in-vitro dialysis tubes outside the body of the patient can be stored, and the in-vivo dialysis tube fixing device is convenient to use. When the extracorporeal dialysis tube is pulled, the buffering assembly can absorb and buffer the pulling force at the first time, the situation that the pulling force directly acts on the skin of a patient, and consequently the patient feels uncomfortable is avoided, and the safety of the peritoneal dialysis device in daily use is improved.

A platform for patient engagement and treatment compliance is disclosed. In an example, a system includes a home therapy machine configured to perform a renal failure therapy treatment. The system also includes a mobile communication device including an application that enables a patient to select a program type for a future renal failure therapy treatment. The application is configured to determine a short program and a long program are available for the future renal failure therapy treatment and cause a user interface to provide an option to select one of the short program or the long program. The application is also configured to receive a selection of the short program or the long program via the user interface and transmit a message to the home therapy machine, the message indicative of the selection of the short program or the long program for the future renal failure therapy treatment.

The invention belongs to the technical field of biological medicines, and particularly discloses a liposome containing a natural extract composition as well as a preparation method and application of the liposome. The method for preparing the liposome containing the natural extract composition comprises the following steps: S1, adding the grape, poria cocos and apple extract, cholesterol and lecithin into an organic solvent, heating, stirring and dissolving to obtain an organic phase; adding the soybean extract and the ginseng extract into ultrapure water, heating and stirring to obtain a water phase; and S2, slowly adding the organic phase into the water phase while stirring, continuing stirring and emulsifying, and removing the organic solvent by reduced pressure distillation to obtain a liposome suspension. And S3, filtering the suspension, adding a freeze-drying protective additive, and freeze-drying to obtain the liposome. The invention also covers the application of the liposome in treating renal failure. In the invention, through the combination of natural extracts and the combination of a specific composition and liposome administration, the components generate a synergistic effect, and the pharmaceutical composition has a remarkable treatment effect on renal failure, especially chronic renal failure.

The present invention relates to the use of 3,4-dihydro-2H-benzo-[1,4]oxazine drugs or salts thereof in the preparation of drugs for inhibiting ferroptosis, in particular to the use of 3,4-dihydro-2H-benzo-[1,4]oxazine compounds or salts thereof in the preparation of drugs for treating ferroptosis-related diseases, wherein the ferroptosis-related diseases include brain trauma, stroke, cardiovascular disease, liver and kidney failure, inflammation and neurodegenerative diseases, such as Parkinson's disease and schizophrenia.

An object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases compared to already known monotherapies. A further object of the present invention is to provide a combination of pharmaceutical active ingredients for treating cardiovascular diseases, particularly cardiac and renal failure, characterized by chronic sodium retention, which reduces patient mortality and / or morbidity. Another object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases by administering a combination comprising finerenone and an SGLT2 inhibitor. [Solution] The present invention relates to pharmaceutical compositions and combinations comprising finerenone or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof, and an SGLT2 inhibitor or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof. The combinations can be used for the treatment and / or prevention of cardiovascular and / or renal diseases in humans and other mammals.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronic kidney failure.

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

A renal failure blood therapy system includes a memory device storing a therapy target for a patient. The system also includes a processor configured to receive the therapy target for the patient, receive a desired solute concentration for the patient, and apply the therapy target and the desired solute concentration as inputs to an optimization routine. The processor is also configured to execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate or a dialysis therapy dialysate flow rate. The processor is further configured to display the at least one dialysis therapy prescription for confirmation or selection by a clinician and transmit the selected or confirmed dialysis therapy prescription to a dialysis machine for a subsequent dialysis treatment for the patient.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronicap kidney failure.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the disinfection.

The present invention provides an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce organ dysfunction or organ failure. In a preferred embodiment, the invention provides an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce renal dysfunction or renal failure or hepatic dysfunction or hepatic failure.

The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and / or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and / or reversing) one or more symptoms of COPD.

The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and / or angiotensin AII antagonists and the use thereof for the treatment and / or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and / or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by hundreds of fluid filled cysts that form in the kidney, resulting in kidney failure. Cysts form when the PKDl gene is inactivated. The present disclosure has found a specific target for therapy, an alternative DNA structure called G4 DNA in the PKDl gene is responsible for cyst formation. G4 DNA is a targetable structure, so the present disclosure provides specific nucleic acid inhibitors of G4 formation, and G4 structure destabilization, thereby blocking G4 DNA and cyst formation in at risk individuals for developing polycystic kidney disease, for example, ADPKD.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Disclosed herein is a method of treating cachexia in a subject. According to some embodiments of the present disclosure, the method includes administering to the subject an effective amount of a recombinant antibody or a fragment thereof, which exhibits a binding affinity and a neutralizing effect on parathyroid hormone-related protein. According to certain embodiments of the present disclosure, the cachexia is caused by a parathyroid hormone-related protein (PTHrP)-expressing cancer, chronic kidney disease, kidney failure, heart failure, or tuberculosis.